Cargando…
Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
A randomized, double‐blind clinical trial was conducted to investigate long‐term abuse effects of testosterone cypionate (TC). Thirty‐one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC. A pharmacokinetic/pharmacodynamic (PK/PD) model w...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915615/ https://www.ncbi.nlm.nih.gov/pubmed/29436172 http://dx.doi.org/10.1002/psp4.12287 |
_version_ | 1783316901693227008 |
---|---|
author | Bi, Youwei Perry, Paul J. Ellerby, Michael Murry, Daryl J. |
author_facet | Bi, Youwei Perry, Paul J. Ellerby, Michael Murry, Daryl J. |
author_sort | Bi, Youwei |
collection | PubMed |
description | A randomized, double‐blind clinical trial was conducted to investigate long‐term abuse effects of testosterone cypionate (TC). Thirty‐one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC. A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize testosterone concentrations and link exposure to change in luteinizing hormone and spermatogenesis following long‐term TC administration. A linear one‐compartment model best described the concentration‐time profile of total testosterone. The population mean estimates for testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution. Weight, albumin, and their changes from baseline were identified as significant covariates for testosterone. The estimated potency of total testosterone (tT) with respect to suppression of luteinizing hormone (LH) synthesis was 9.33 ng/mL. Simulation based on the indirect response model suggests the suppression of endogenous testosterone secretion, LH synthesis, and spermatogenesis was more severe and of greater duration in the 250 mg and the 500 mg dose groups. |
format | Online Article Text |
id | pubmed-5915615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59156152018-04-25 Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects Bi, Youwei Perry, Paul J. Ellerby, Michael Murry, Daryl J. CPT Pharmacometrics Syst Pharmacol Article A randomized, double‐blind clinical trial was conducted to investigate long‐term abuse effects of testosterone cypionate (TC). Thirty‐one healthy men were randomized into a dose group of 100, 250, or 500 mg/wk and received 14 weekly injections of TC. A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to characterize testosterone concentrations and link exposure to change in luteinizing hormone and spermatogenesis following long‐term TC administration. A linear one‐compartment model best described the concentration‐time profile of total testosterone. The population mean estimates for testosterone were 2.6 kL/day for clearance and 14.4 kL for volume of distribution. Weight, albumin, and their changes from baseline were identified as significant covariates for testosterone. The estimated potency of total testosterone (tT) with respect to suppression of luteinizing hormone (LH) synthesis was 9.33 ng/mL. Simulation based on the indirect response model suggests the suppression of endogenous testosterone secretion, LH synthesis, and spermatogenesis was more severe and of greater duration in the 250 mg and the 500 mg dose groups. John Wiley and Sons Inc. 2018-03-01 2018-04 /pmc/articles/PMC5915615/ /pubmed/29436172 http://dx.doi.org/10.1002/psp4.12287 Text en © 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Article Bi, Youwei Perry, Paul J. Ellerby, Michael Murry, Daryl J. Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects |
title | Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects |
title_full | Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects |
title_fullStr | Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects |
title_full_unstemmed | Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects |
title_short | Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects |
title_sort | population pharmacokinetic/pharmacodynamic modeling of depot testosterone cypionate in healthy male subjects |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915615/ https://www.ncbi.nlm.nih.gov/pubmed/29436172 http://dx.doi.org/10.1002/psp4.12287 |
work_keys_str_mv | AT biyouwei populationpharmacokineticpharmacodynamicmodelingofdepottestosteronecypionateinhealthymalesubjects AT perrypaulj populationpharmacokineticpharmacodynamicmodelingofdepottestosteronecypionateinhealthymalesubjects AT ellerbymichael populationpharmacokineticpharmacodynamicmodelingofdepottestosteronecypionateinhealthymalesubjects AT murrydarylj populationpharmacokineticpharmacodynamicmodelingofdepottestosteronecypionateinhealthymalesubjects |